Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Solid Tumor | Active, not recruiting | Phase 2 | 2022-02-17 | NCT03865082 | |
| A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2021-04-15 | NCT04126876 |